Product Name:Eptifibatide Acetate
Form:Acetate salt
Purity:95%
Storage:-20oC
Cas No:148031-34-9
Molar Mass:832
Chemical Formula:C35H49N11O9S2
Synonyms:Integrilin
IUPAC Name:2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
SMILES:C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N
InChIKey:CZKPOZZJODAYPZ-UHFFFAOYSA-N
InChI:InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)
Sequence:CXGDWPC
Target:GP IIb/IIIa
Application:Eptifibatide Acetate is a potent glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitor, used in cardiovascular medicine to prevent platelet aggregation and thrombus formation. It is widely used in acute coronary syndrome (ACS) and percutaneous coronary intervention (PCI) to reduce the risk of heart attacks and ischemic complications. By blocking fibrinogen binding to platelets, Eptifibatide prevents clot formation without affecting coagulation factors. Current research explores its role in stroke prevention, neurovascular protection, and alternative antithrombotic strategies, making it a critical agent in interventional cardiology and thrombotic disorder management.
Current Research:Eptifibatide Acetate is a cyclic heptapeptide antiplatelet drug that selectively inhibits glycoprotein IIb/IIIa (GP IIb/IIIa) receptors on platelets, preventing fibrinogen-mediated platelet aggregation. It is primarily used in acute coronary syndrome (ACS), percutaneous coronary intervention (PCI), and thrombosis prevention. While its established role is in cardiology, emerging research is evaluating its potential applications in stroke management, neurovascular protection, and alternative antithrombotic therapies. Acute Coronary Syndrome (ACS) and PCI Applications Eptifibatide is a standard therapy in patients undergoing angioplasty and stent placement to reduce ischemic complications. Thrombosis prevention in high-risk patients: Studies confirm its effectiveness in reducing myocardial infarction (MI) and revascularization risks in ACS patients undergoing PCI. Comparison with other GP IIb/IIIa inhibitors: Ongoing research compares Eptifibatide with abciximab and tirofiban, focusing on efficacy, bleeding risks, and cost-effectiveness. Optimizing dosing regimens: New clinical trials assess low-dose strategies to reduce bleeding complications while maintaining antiplatelet efficacy. Neurovascular Research and Stroke Prevention Given its strong antiplatelet effects, researchers are exploring Eptifibatide for stroke prevention and treatment. Acute ischemic stroke (AIS): Some studies suggest that Eptifibatide may improve cerebral blood flow and prevent thrombus reformation after thrombolysis or mechanical thrombectomy. Neuroprotection in brain ischemia: Preclinical models indicate that Eptifibatide may help reduce infarct size and improve outcomes in stroke patients. Safety in hemorrhagic stroke risk: Researchers are working on identifying stroke subtypes where Eptifibatide could be safely administered without increasing bleeding risks. Alternative Antithrombotic Strategies and Combination Therapies Dual antiplatelet therapy (DAPT) enhancement: Studies are evaluating Eptifibatide combined with P2Y12 inhibitors (e.g., clopidogrel, ticagrelor) to enhance platelet inhibition in high-risk patients. Bridging therapy for surgery: Research suggests that short-acting GP IIb/IIIa inhibitors like Eptifibatide may be useful in patients requiring temporary antiplatelet discontinuation before surgery. Microvascular thrombosis prevention: Emerging studies investigate its potential in sepsis-associated thrombosis, small-vessel disease, and vascular inflammation. Emerging Research Areas Cardiovascular disease in diabetes: Studies explore whether Eptifibatide can improve cardiovascular outcomes in diabetic patients who have a higher risk of thrombosis. Atrial fibrillation (AF) management: Researchers are assessing its role in stroke prevention in non-valvular AF as an adjunct or alternative to oral anticoagulants. Cancer-associated thrombosis: Given the hypercoagulable state in cancer patients, Eptifibatide is being evaluated for its role in preventing cancer-associated thrombosis. With expanding research, Eptifibatide Acetate remains a critical agent in cardiovascular medicine while showing potential in neurovascular and thrombotic disorder management.
Get a Quote
LinkPeptide
